Phase I
Sutro Biopharma presented Phase I data at (AACR) showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
The company’s shares rose by 29.6% on NASDAQ shortly after the announcement.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
PRESS RELEASES